Shares fell as much as 3% in early Frankfurt trading. They were up more than 60% over the last 12 months through Tuesday’s close.
(March 4): Bayer AG forecast little change in profit and sales in 2026 as the German agriculture and health company grapples with generic competition for its blockbuster blood thinner and continued uncertainty over its efforts to contain a pesticide litigation in the US.
Adjusted earnings before interest, taxes, depreciation and amortisation will probably reach between €9.6 billion and €10.1 billion this year on a currency-adjusted basis, the company said on Wednesday. That compares with a €9.75 billion average estimate from analysts and last year’s decline to €9.67 billion.
